TIDMIMM
RNS Number : 4907X
Immupharma PLC
24 November 2017
24 NOVEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces the
approval of the grant of options over a total of 7,875,000 ordinary
shares of 10p each in the Company ("Ordinary Shares") to certain of
its Directors, non-executive Directors, employees and consultants
representing 5.26% of ImmuPharma's Ordinary Shares and total voting
rights on a fully diluted basis (the "Options").
The exercise price for the Options is 98.62 pence being the
closing middle market share price on 23 November 2017. The Options
will vest subject to certain conditions after three years and are
exercisable between three and ten years from the date of grant.
Options granted to Executive Directors and employees
Upon the recommendation of the Company's remuneration committee,
the Company has granted 4,875,000 of the Options to the Company's
Executive Directors and certain other employees pursuant to the
Company's Share Option Plan which was adopted on 30 March 2017 (the
"2017 Plan"). The amount of Options granted on 24 November 2017 to
the Executive Directors is summarised in the following table:
Director Ordinary Shares under
Option
------------------- ----------------------
Dimitri Dimitriou 1,500,000
------------------- ----------------------
Robert Zimmer 1,875,000*
------------------- ----------------------
*includes 375,000 Options granted to Elisabeth Zimmer, Robert
Zimmer's wife, who is also an employee of the Company.
Messrs Dimitriou and Zimmer currently have the following
interests in issued Ordinary Shares:
Director Number of Ordinary % of issued share
Shares capital at 24
November 2017
------------------- ------------------- ------------------
Dimitri Dimitriou 3,567,430 2.69
------------------- ------------------- ------------------
Robert Zimmer 25,344,514* 19.12
------------------- ------------------- ------------------
*includes 792,961 shares held by Elisabeth Zimmer, Robert
Zimmer's wife, who is also an employee of the Company.
Following the grant of the options referred to above, Messrs
Dimitriou and Zimmer will have the following interests in share
options in the Company:
Director Number of Exercise Price Expiry Date
options
------------------ ------------ --------------- ------------
Dimitri Dimitriou 140,000 86.50p 04.02.2019
1,000,000 50.25p 30.03.2027
1,500,000 98.62p 24.11.2027
------------------ ------------ --------------- ------------
Robert Zimmer 200,000* 86.50p 04.02.2019
50,000* 90.75p 24.11.2021
100,000* 43.88p 02.06.2026
1,250,000* 50.25p 30.03.2027
1,875,000* 98.62p 24.11.2027
------------------ ------------ --------------- ------------
*includes options granted to Elisabeth Zimmer, Robert Zimmer's
wife, who is also an employee of the Company
Following this grant of Options summarised above, the total
number of share options outstanding pursuant to the 2017 Plan will
be 8,125,000 representing 6.15% of ImmuPharma's Ordinary Shares and
total voting rights on a fully diluted basis. 2,005,000 Options
remain outstanding pursuant to the Company's previous share option
plan. Together, there are 10,130,000 Options outstanding
representing 7.64% of ImmuPharma's Ordinary Shares and total voting
rights on a fully diluted basis.
Options granted to Non-executive Directors
The Company has also granted certain Options to Non-executive
Directors as summarised in the following table:
Director Ordinary Shares under
Option
----------------- ----------------------
Tim McCarthy 1,500,000
----------------- ----------------------
Franco di Muzio 300,000
----------------- ----------------------
Stephane Mery 300,000
----------------- ----------------------
Messrs McCarthy, di Muzio and Mery currently have the following
interests in issued Ordinary Shares:
Director Number of Ordinary % of issued share
Shares capital at 23
November 2017
----------------- ------------------- ------------------
Tim McCarthy 38,462 0.03%
----------------- ------------------- ------------------
Franco di Muzio 99,412 0.08%
----------------- ------------------- ------------------
Stephane Mery 21,490 0.02%
----------------- ------------------- ------------------
Following the grant of the Options referred to above, Messrs
McCarthy, di Muzio and Mery will have the following interests in
options over the Company's Ordinary Shares:
Director Number of Exercise Price Expiry Date
Ordinary Shares
under Option
-------------- ----------------- --------------- ------------
Tim McCarthy 500,000 43.88p 02.06.2026
1,000,000 56.75p 12.07.2027
1,500,000 98.62p 24.11.2027
-------------- ----------------- --------------- ------------
Franco di 100,000 86.50p 04.02.2019
Muzio
100,000 43.88p 02.06.2026
200,000 56.75p 12.07.2027
300,000 98.62p 24.11.2027
-------------- ----------------- --------------- ------------
Stephane Mery 100,000 43.88p 02.06.2026
200,000 56.75p 12.07.2027
300,000 98.62p 24.11.2027
-------------- ----------------- --------------- ------------
Total Share Options
As stated above, the total options outstanding under both the
2017 Plan and the Company's previous share option plan is
10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and
total voting rights on a fully diluted basis. The total options
outstanding that have been granted to non-employees and consultants
is 5,185,000. The total warrants outstanding is 153,850. Taken
altogether, there are currently 15,468,850 outstanding options and
warrants, representing 11.67% of ImmuPharma's Ordinary Shares and
total voting rights on a fully diluted basis.
This announcement contains inside information for the purpose of
Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
ImmuPharma plc (www.immupharma.co.uk)
--------------------------------------- ---------------------
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor +44 (0) 20 7152
Relations 4080
Twitter: @immupharma +44 (0) 7721 413496
--------------------------------------- ---------------------
Northland Capital Partners Limited
(NOMAD & Broker)
Patrick Claridge, Corporate
Finance
David Hignell, Corporate Finance
Jamie Spotswood, Corporate Finance +44 (0) 20 3861
Rob Rees, Corporate Broking 6625
--------------------------------------- ---------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEBIBTTMBATBIR
(END) Dow Jones Newswires
November 24, 2017 08:32 ET (13:32 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
